BMBF

EQS-News: aap closes Q1 2024 with sales growth of 5.6% and positive developments at all operating levels and makes a strong start to Q2 2024

Retrieved on: 
Friday, May 3, 2024
Investment, German, Education, Health care, Guideline, BMBF, Patient, AAP, Health, MDR, Bank statement, Clinical trial, Growth, Pharmaceutical industry

An order placed from the Middle East had to be postponed to Q2 2024 at the customer's request, meaning that the EMEA region cannot report any growth.

Key Points: 
  • An order placed from the Middle East had to be postponed to Q2 2024 at the customer's request, meaning that the EMEA region cannot report any growth.
  • aap is confident that the investments in aap systems made in Q1 2024 will sustainably strengthen the business in the region.
  • This would enable an earlier completion of the follow-up phase and an earlier start to the approval and industrialization phase.
  • The Management Board therefore remains confident about the Company's positive development in 2024.

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

Retrieved on: 
Monday, April 22, 2024
Bone marrow, FQR, CRISPR, Nature Biotechnology, Safety, Education, Pharmacokinetics, Infection, Neutropenia, Survival, AMR, Febrile neutropenia, Gene editing, Partnership, Bloodstream infections, Development, BMBF, Escherichia coli, Research and development, Patient, Quinolone antibiotic, Synthetic biology, HSCT, Pharmaceutical industry

Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.

Key Points: 
  • Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.
  • Despite the significant advances in hematologic cancer therapy over the past decade, infectious complications, and antimicrobial resistance (AMR) continue to pose significant threats to patients and clinical outcomes1.
  • Currently, there are no approved therapies for the prevention of bloodstream infections (BSIs) in hematological cancer patients.
  • SNIPR Biome is developing SNIPR001 to address this urgent unmet need to combat infections in hematological cancer patients.

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

Retrieved on: 
Monday, April 22, 2024
Bone marrow, FQR, CRISPR, Nature Biotechnology, Safety, Education, Pharmacokinetics, Infection, Neutropenia, Survival, AMR, Febrile neutropenia, Gene editing, Partnership, Bloodstream infections, Development, BMBF, Escherichia coli, Research and development, Patient, Quinolone antibiotic, Synthetic biology, HSCT, Pharmaceutical industry

Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.

Key Points: 
  • Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.
  • Despite the significant advances in hematologic cancer therapy over the past decade, infectious complications, and antimicrobial resistance (AMR) continue to pose significant threats to patients and clinical outcomes1.
  • Currently, there are no approved therapies for the prevention of bloodstream infections (BSIs) in hematological cancer patients.
  • SNIPR Biome is developing SNIPR001 to address this urgent unmet need to combat infections in hematological cancer patients.

SCOUT RECEIVES FUNDING FROM CARB-X TO DEVELOP A LOW-COST POINT-OF-CARE AND HOME DIAGNOSTIC FOR GONORRHEA AND CHLAMYDIA

Retrieved on: 
Thursday, April 18, 2024
Chlamydia trachomatis, FDA, Mortality, Administration, Pelvic inflammatory disease, Malaria, Death, Doctor of Philosophy, Vaccine, Development, Point-of-care testing, PHAC, Diagnosis, Gonorrhea, Novo Nordisk Foundation, Prevalence, HHS, Vertical loop, Neonatal sepsis, Infertility, OTC, Public Health Agency, Entrepreneurship, Infection, Urine, Neisseria gonorrhoeae, Patient, Ng, CARB-X, NIH, Education, BMBF, STI, Therapy, Disease, Bangladesh Technical Education Board, SARS-CoV-2, HIV/AIDS, Social work, NIAID, Bill, Physician

BOSTON, April 18, 2024 /PRNewswire/ -- Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1 million to diagnostics and health tech company Scout to demonstrate proof-of-concept and feasibility ahead of development of a new point-of-care test – STI Scout. The test will detect and differentiate between Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct). STI Scout is quick and inexpensive, with a turnaround time of 30 minutes and costs anticipated to be less than half of other options.

Key Points: 
  • STI Scout is quick and inexpensive, with a turnaround time of 30 minutes and costs anticipated to be less than half of other options.
  • Additionally, STI Scout can use either first void urine or vaginal swabs, and future tests will be able to guide therapy for gonorrhea treatment based on antibiotic susceptibility.
  • STI Scout uses the Scout Hub to run and the Scout Connect mobile app, which provides instructions, tracks results, and eventually will allow patients to connect digitally to a healthcare provider.
  • Scout's diagnostic is the second diagnostic and ninth project to receive a CARB-X award as part of the 2022-2023 funding call .

EQS-News: Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams

Retrieved on: 
Wednesday, April 10, 2024
Climate change, Education, Drink, TVC, BRAIN, Food, Plant, Wine, Applied science, BMBF

Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams

Key Points: 
  • Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams
    The issuer is solely responsible for the content of this announcement.
  • The aim of the “SusBev” project is to use and ferment agricultural residues and side streams from viticulture and other regional agricultural processes to produce healthy and tasty beverages and food.
  • In addition, their resistance to fungal attack means that the plants require less pesticide treatment, making them safe for consumption.
  • BRAIN Biotech AG, Tropical Viticulture Consultants (TVC), Zukunftsweine GmbH (ZW) and Provadis Hochschule are participating in the SusBev project.

Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

Retrieved on: 
Tuesday, April 9, 2024
Colistin, Beta-lactam, Education, Development, Partnership, Patient, HHS, Gram-negative bacteria, Escherichia coli, World Health Organization, Infection, USD, Administration, Antibiotic, BMBF, Pharmaceutical industry

The grant award is to support initial preclinical activities on the antibiotics program recently acquired from Spexis.

Key Points: 
  • The grant award is to support initial preclinical activities on the antibiotics program recently acquired from Spexis.
  • Basilea could receive additional funding from CARB-X, to continue preclinical and early clinical development of the antibiotics program, if the project achieves certain milestones.
  • The program comprises antibiotics targeting LptA, which is part of the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria.
  • The molecules belong to one of the very few novel classes of antibiotics in development.

EQS-News: After a mixed 2023 financial year, aap makes a strong start to the 2024 financial year

Retrieved on: 
Thursday, February 15, 2024
ISO, Spine, MDR, ISO 13485, Notified body, German, AAP, Elective surgery, EUR, Certification, Health, Guideline, Acceleration, Clinical trial, BMBF, Trauma, MDD, Education, Pharmaceutical industry

After a mixed 2023 financial year, aap makes a strong start to the 2024 financial year

Key Points: 
  • After a mixed 2023 financial year, aap makes a strong start to the 2024 financial year
    The issuer is solely responsible for the content of this announcement.
  • In the past financial year, aap Implantate AG ("aap" or "Company") was able to significantly accelerate patient recruitment with the realignment of the world's first clinical human study for its innovative antibacterial implant technology.
  • Building on these promising developments, aap will continue its efforts to attract significant third-party funding for the industrial expansion of the technology in the 2024 financial year.
  • After a mixed 2023 financial year in the LOQTEQ® trauma division, aap was able to make a positive start to the new 2024 financial year.

Real-World Data on Human Milk-Based Fortification Reveals Limitations of Protocol Designs of Two RCTs

Retrieved on: 
Tuesday, February 6, 2024
Growth, Mortality, Bronchopulmonary dysplasia, Hospice and palliative medicine, NEC, Standard of care, BPD, NICU, Disease, Patient, Incidence, Sepsis, RCT, Clinical study design, Isabella Tree, BMBF, Risk, Exclusive, Vulnerable, FAAP, Birth weight, Standard, Necrotizing enterocolitis, Gestational age, Hospital, Dietary supplement

DUARTE, Calif., Feb. 6, 2024 /PRNewswire/ -- Optimizing nutrition for premature infants remains an important focus in neonatal care. More than 20 peer-reviewed studies of 5,000+ preterm infants demonstrated that, compared to bovine milk-based fortifiers (BMBF), Prolacta Bioscience's human milk-based fortifiers (HMBF) improve growth and development1-7 and provide clinically significant reductions in comorbidities.1,2,8-20 The health benefits from the use of HMBF have also shown significant annual cost savings for hospitals.8 More than 100,000 critically ill and preterm infants have received Prolacta's human milk-based nutritional products.21

Key Points: 
  • While the RCTs were intended to provide a head-to-head comparison between fortifier products, the feeding protocols fundamentally differed.
  • HMBF recommendations for best outcomes regarding the day fortification should begin and the speed at which feeds are advanced were not followed in either study.
  • Given these known risks, randomizing extremely premature infants to day-one fortification with BMBF would unjustly endanger this vulnerable patient population.
  • Extensive real-world data affirm EHMD adoption enables critical health improvements for premature infants and major cost reductions for hospitals.

Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections

Retrieved on: 
Tuesday, January 16, 2024
Development, Agreement, Patient, Infection, Ceftriaxone, Infertility, Social work, Science, Gonorrhea, STI, Administration, Pelvic inflammatory disease, Vaccination, Bill, Risk, Education, Bacteria, Neisseria gonorrhoeae, Disease, BMBF, Doctor of Philosophy, HIV, Human services, Vaccine, Chronic pain, DHSC, OMV

The Neisseria gonorrhoeae bacterium causes gonorrhea, the second most reported bacterial STI.

Key Points: 
  • The Neisseria gonorrhoeae bacterium causes gonorrhea, the second most reported bacterial STI.
  • Patients with gonorrhea can face serious health effects, including pelvic inflammatory disease, chronic pain, infertility, and an increased risk of contracting HIV.
  • Through the tailored gonococcal antigens on the surface of the meningococcal OMV, Intravacc anticipates a significant enhancement in the vaccine candidate’s efficacy against gonorrhea.
  • “This CARB-X project allows us to combine our science and OMV expertise for the development of a vaccine against gonorrhea infections.

More than 100 patients included in the human clinical trial by 31 December 2023; adapted study design meets expectations for accelerated patient recruitment

Retrieved on: 
Saturday, January 13, 2024
Education, Innovation system, AAP, Patient, Clinical trial, Medicine, Traumatology, BMBF, Trial of the century, Health, Pharmaceutical industry

Further successful compassionate use cases make aap optimistic that corresponding results will also be achieved in the human clinical trial.

Key Points: 
  • Further successful compassionate use cases make aap optimistic that corresponding results will also be achieved in the human clinical trial.
  • Depending on the human clinical trial and the regulatory authorities, aap expects the first market launch of its new technology in three years.
  • The human clinical study is funded by the Federal Ministry of Education and Research ("BMBF").
  • According to the BMBF, projects on the topic of "Transferring medical technology solutions to patient care - proving clinical evidence without delay" are being funded.